Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.50 |
| ▸ | TST | Q16762 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | MANBA | O00462 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascorbic Acid SCHEMBL325827 | 0.87 | MAPT (0.78) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL28456797 | 0.87 | MAPT (0.78) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL1533996 | 0.86 | MAPT (0.89) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL17888786 | 0.85 | MAPT (0.86) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL30327382 | 0.85 | MAPT (0.86) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL31487361 | 0.85 | MAPT (0.86) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL15577247 | 0.85 | MAPT (0.93) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL27955458 | 0.85 | MAPT (0.93) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL28240604 | 0.85 | MAPT (0.93) | LMNAMAPTL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL10957988 | 0.84 | MAPT (1.00) | LMNAMAPTL3MBTL1HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8702813-B2 | Use of ascorbic acid derivatives for dyeing keratin-containing fibres | MERCK PATENT GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20130228192-A1 | USE OF ASCORBIC ACID DERIVATIVES FOR DYEING KERATIN-CONTAINING FIBRES | MERCK PATENT GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| EP-1621582-B1 | RESIN COMPOSITION AND PROCESS FOR PRODUCING THE SAME | KANEKA CORP (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7838586-B2 | Resin composition and process for producing the same | KANEKA CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20060211799-A1 | Resin composition and process for producing the same | KANEKA CORPORATION (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1621582-A1 | RESIN COMPOSITION AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1104415-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | Triangle Pharmaceuticals Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009494-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130228192-A1 | USE OF ASCORBIC ACID DERIVATIVES FOR DYEING KERATIN-CONTAINING FIBRES | KRT18, PROC, DSG1 | LMNA 310/4885MAPT 313/4885L3MBTL1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.